Sanofi Genzyme
500 Kendall Street
Cambridge
Massachusetts
02142
United States
Tel: 617-252-7500
Fax: 617-252-7600
Website: https://www.sanofigenzyme.com/
About Sanofi Genzyme
About Genzyme
Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
776 articles about Sanofi Genzyme
-
Genzyme Corporation Reports Financial Results For Fourth Quarter Of 2005 And Full Year
2/15/2006
-
Genzyme Corporation Launches Key Test To Monitor Gleevec(R) Resistance
2/9/2006
-
Genzyme Corporation Granted Label Change For Thyrogen
2/1/2006
-
Genzyme Corporation Pompe Drug Gets Positive Opinion In Europe
1/27/2006
-
Tripos Discovery Research Centre Announces Partnerships With Industry-Leading Pharmaceutical And Life Science Companies
1/25/2006
-
Genzyme Corporation Provides Update On U.S. Marketing Application For Myozyme(R); FDA Extends Review Period
1/17/2006
-
De Novo Pharmaceuticals Ltd. Announces Drug Discovery Collaboration With Genzyme Corporation
1/17/2006
-
Genzyme Corporation Reports 22 Percent Increase In Fourth-Quarter Revenue
1/10/2006
-
Genzyme Corporation Named One Of FORTUNE's '100 Best Companies To Work For'
1/9/2006
-
Genzyme Corporation Picks Up Gene Therapy Business From Avigen, Inc.
12/21/2005
-
Competitive Technologies, Inc. Licenses Homocysteine Assay To Genzyme Corporation
12/21/2005
-
Avigen, Inc.'s Gene Therapy Technology Acquired By Genzyme Corporation
12/21/2005
-
Avigen, Inc. To Hold Conference Call Today To Discuss Genzyme Corporation Acquisition Of Its Gene Therapy Assets
12/21/2005
-
Crucell N.V. Announces STAR(TM) Licensing Agreement With Genzyme Corporation
12/19/2005
-
BioSpace, Inc. And Massachusetts Biotechnology Council, Inc. Unveil 2006 Genetown™ Campaign
12/15/2005
-
Dyax Corp. And Genzyme Corporation Initiate Pivotal Phase III Trial Of Subcutaneously Administered DX-88 For The Treatment Of Hereditary Angioedema
12/8/2005
-
Genzyme Corporation Launches Colorectal Cancer Test To Determine Appropriate Camptosar(R) Dosage
12/6/2005
-
U.S. FDA Warns About Schering AG And Genzyme Corporation Drug In MS Trial
11/30/2005
-
Macrozyme Announces A Collaboration With Genzyme Corporation In Diabetes And Other Possible Indications
11/24/2005
-
Genzyme Corporation Acquires Cell Genesys, Inc. Manufacturing Site
11/22/2005